JPRN-UMIN000001772已完成2 期
The clinical study on immunotherapy for advanced renal cell carcinoma =Combination therapy of natural IFN-alfa and meloxicam against metastatic renal cell crcinoma= - Combination therapy with meloxicam, a COX-2 inhibitor, and interferon alfa for metastatic renal cell carcinoma
Hokkaido Advanced Renal Cell Carcinoma Treatment Group0 个研究点目标入组 50 人开始时间: 2009年3月13日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
The combination of IFN-alfa and meloxicam is considered to be an effective therapy that achieves a higher response rate compared with that previously reported for IFN- monotherapy.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. prior immunotherapy 2. Brain metastasis 3. Bone metastasis alone 4. active double cancers 5. Liver cirrhosis 6. uncontolled DM 7. Depression
研究者
相似试验
尚未招募
不适用
An integrated immunological-pharmacological approach to improve long-term allograft functiograft failurekidney transplantation10029149NL-OMON45414Inwendige Geneeskunde - Nefrologie en Transplantatie420
终止
1 期
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell LymphomaCutaneous T-cell LymphomaNCT02061449NYU Langone Health3
终止
不适用
Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory DiseasesInflammatory Bowel DiseasesNCT03370601University Hospital, Lille9
已完成
1 期
Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for MelanomaMelanomaNCT01608594Diwakar Davar30
招募中
不适用
Combination therapy of interferon-alpha and interleukin-2 for patients with metastatic renal cell carcinoma after failure of targeted therapy because of adverse eventsJPRN-UMIN000017717Department of Urology, The University of Tokyo Hospital30